Combination of sepsis biomarkers may indicate an invasive fungal infection in haematological patients

References

• Aimoto, M., et al., 2014. Diagnostic performance of serum high-sensitivity procalcitonin and serum C-reactive protein tests for detecting bacterial infection in febrile neutropenia. Infection, 42 (6), 971–979.
   PubMed Web of Science ®Google Scholar
• Averbuch, D., on behalf of ECIL4, a joint venture of EBMT, EORTC, ICHS, ESGICH/ESCMID and ELN. et al., 2013. European guidelines for empirical antibacterial therapy for febrile neutropenic patients in the era of growing resistance: summary of the 2011 4th European Conference on Infections in Leukemia. Haematologica, 98 (12), 1826–1835.
   PubMed Web of Science ®Google Scholar
• Blijlevens, N.M., et al., 2000. Procalcitonin does not discriminate infection from inflammation after allogeneic bone marrow transplantation. Clinical and diagnostic laboratory immunology, 7 (6), 889–892.
   PubMedGoogle Scholar
• Bloodstream Infection Event (Central Line-Associated Bloodstream Infection and Non-central Line Associated Bloodstream Infection) 2018. Available from: https://www.cdc.gov/nhsn/pdfs/pscmanual/4psc_clabscurrent.pdf. [Accessed 13 March 2018].
   Google Scholar
• De Pauw, B., et al., 2008. Revised Definitions of Invasive Fungal Disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clinical infectious diseases, 46 (12), 1813–1821.
   PubMed Web of Science ®Google Scholar
• DeLong, E.R., DeLong, D.M., and Clarke-Pearson, D.L., 1988. Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics, 44 (3), 837–845.
   PubMed Web of Science ®Google Scholar
• Fleischhack, G., et al., 2000. Procalcitonin—a sensitive inflammation marker of febrile episodes in neutropenic children with cancer. Intensive care medicine, 26 (2), S202–S211.
   PubMedGoogle Scholar
• Freifeld, A.G., Infectious Diseases Society of America et al., 2011. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the infectious diseases society of america. Clinical infectious diseases, 52 (4), e56–e93.
   PubMed Web of Science ®Google Scholar
• Hoenigl, M., et al., 2012. European Organization for the Research and Treatment of Cancer/Mycoses Study Group (EORTC/MSG) host factors and invasive fungal infections in patients with haematological malignancies. The journal of antimicrobial chemotherapy, 67 (8), 2029–2033.
   PubMed Web of Science ®Google Scholar
• Hoenigl, M., et al., 2011. Epidemiology of invasive fungal infections and rationale for antifungal therapy in patients with haematological malignancies. Mycoses, 54 (5), 454–459.
   PubMed Web of Science ®Google Scholar
• Hope, W.W., et al., 2007. Pathogenesis of Aspergillus fumigatus and the kinetics of galactomannan in an in vitro model of early invasive pulmonary aspergillosis: implications for antifungal therapy. The journal of infectious diseases, 195 (3), 455–466.
   PubMed Web of Science ®Google Scholar
• Kim, D.Y., et al., 2011. The usefulness of procalcitonin and C-reactive protein as early diagnostic markers of bacteremia in cancer patients with febrile neutropenia. Cancer research and treatment, 43 (3), 176–180.
   PubMed Web of Science ®Google Scholar
• Lamoth, F., and Calandra, T., 2017. Early diagnosis of invasive mould infections and disease. Journal of antimicrobial chemotherapy, 72 (suppl_1), i19–i28.
   PubMedGoogle Scholar
• Maertens, J., et al., 2009. Galactomannan serves as a surrogate endpoint for outcome of pulmonary invasive aspergillosis in neutropenic hematology patients. Cancer, 115 (2), 355–362.
   PubMed Web of Science ®Google Scholar
• Marková, M., et al., 2013. Substantially elevated C-reactive protein (CRP), together with low levels of procalcitonin (PCT), contributes to diagnosis of fungal infection in immunocompromised patients. Supportive care in cancer, 21 (10), 2733–2742.
   PubMed Web of Science ®Google Scholar
• Marr, K.A., et al., 2004. Detection of galactomannan antigenemia by enzyme immunoassay for the diagnosis of invasive aspergillosis: variables that affect performance. The journal of infectious diseases, 190 (3), 641–649.
   PubMed Web of Science ®Google Scholar
• Martini, A., et al., 2010. Procalcitonin levels in surgical patients at risk of candidemia. The journal of infection, 60 (6), 425–430.
   PubMed Web of Science ®Google Scholar
• Montagna, M.T., Coretti, C., and Caggiano, G., 2011. Procalcitonin: a possible marker of invasive fungal infection in high risk patients? Journal of preventive medicine and hygiene, 52 (1), 38–39.
   PubMedGoogle Scholar
• Montagna, M.T., et al., 2012. Invasive fungal infections in patients with hematologic malignancies (aurora project): lights and shadows during 18-months surveillance. International journal of molecular sciences, 13 (1), 774–787.
   PubMed Web of Science ®Google Scholar
• Pappas, P.G., et al., 2016. Executive summary: clinical practice guideline for the management of candidiasis: 2016 update by the Infectious Diseases Society of America. Clinical infectious diseases, 62 (4), 409–417.
   PubMedGoogle Scholar
• Patterson, T.F., et al., 2016. Practice guidelines for the diagnosis and management of aspergillosis: 2016 update by the Infectious Diseases Society of America. Clinical infectious diseases, 63 (4), e1–e60.
   PubMed Web of Science ®Google Scholar
• Petrikkos, G.L., et al., 2005. Value of measuring serum procalcitonin, C-reactive protein, and mannan antigens to distinguish fungal from bacterial infections. European journal of clinical microbiology & infectious diseases, 24 (4), 272–275.
   PubMed Web of Science ®Google Scholar
• Reinhart, K., and Meisner, M., 2011. Biomarkers in the critically ill patient: procalcitonin. Critical care clinics, 27 (2), 253–263.
   PubMed Web of Science ®Google Scholar
• Shirakawa, K., et al., 2011. Presepsin (sCD14-ST): development and evaluation of one-step ELISA with a new standard that is similar to the form of presepsin in septic patients. Clinical chemistry and laboratory medicine, 49 (5), 937–939.
   PubMed Web of Science ®Google Scholar
• Shozushima, T., et al., 2011. Usefulness of presepsin (sCD14-ST) measurements as a marker for the diagnosis and severity of sepsis that satisfied diagnostic criteria of systemic inflammatory response syndrome. Journal of infection and chemotherapy: Official journal of the Japan society of chemotherapy, 17 (6), 764–769.
   PubMed Web of Science ®Google Scholar
• Tacke, D., et al., 2014. Primary prophylaxis of invasive fungal infections in patients with haematologic malignancies. 2014 update of the recommendations of the Infectious Diseases Working Party of the German Society for Haematology and Oncology. Annals of hematology, 93 (9), 1449–1456.
   PubMed Web of Science ®Google Scholar
• Tissot, F., et al., 2017. ECIL-6 guidelines for the treatment of invasive candidiasis, aspergillosis and mucormycosis in leukemia and hematopoietic stem cell transplant patients. Haematologica, 102 (3), 433–444.
   PubMed Web of Science ®Google Scholar
• Zou, Q., Wen, W., and Zhang, X.-C., 2014. Presepsin as a novel sepsis biomarker. World journal of emergency medicine, 5 (1), 16–19.
   PubMedGoogle Scholar